TABLE 1.

Clinical and demographic features of sarcoid patients

NF-κB/p65 level (no. of patients)Mean age (yr)Avg disease duration (yr)% (n) of patients who were male% (n) who were:% (n) whose treatment lasted >6 mo% (n) with active disease% (n) with worsening disease% (n) undergoing immunosuppressive therapy with:% (n) at radiographic stage I, II, III, and IV% (n) with ≥3 organs involvedaAbsolute CD4+ T-cell countAbsolute CD19+ cell count
African AmericanCaucasianPrednisoneHydroxychloroquineMethotrexateCombination therapy
Normal (11)47.21836 (4)91 (10)9 (1)91 (10)36 (4)0 (0)36 (4)55 (6)9 (1)45 (5)36 (4), 36 (4), 9 (1), 18 (2)9 (1)NormalNormal
Reduced (11)54.19.318 (2)91 (10)9 (1)82 (9)82 (9)55 (6)73 (8)73 (8)45 (5)64 (7)0 (0), 36 (4), 9 (1), 55 (6)36 (4)ReducedReduced
  • a Including lung, upper respiratory tract, skin, bone, liver, and eye.